A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy

Autor: Sung Han Kim, Jongkeun Park, Weon Seo Park, Dongwan Hong, Jinsoo Chung

Publikováno v: Investigative and Clinical Urology, Vol 63, Iss 6, Pp 602-611 (2022)

Purpose: To identify candidate gene mutations to significantly predict the risk of survival prognosis after treatment with systemic first-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) patients. Materials and Methods: Between 2

Externí odkaz: https://doaj.org/article/35975fe258ff4e9eb732313c5e6b181b

Can Incomplete Metastasectomy Impact Renal Cell Carcinoma Outcomes? A Propensity Score Matching Analysis From a Prospective Multicenter Collaboration

Autor: Alice Dragomir, Charles Hesswani, Gautier Marcq, Alan I So, Christian Kollmannsberger, Naveen S. Basappa, Adrian Fairey, Anil Kapoor, Aly-Khan A. Lalani, Antonio Finelli, Lori A Wood, Daniel Y.C. Heng, Georg Bjarnason, Rodney H. Breau, Luke T. Lavallée, Denis Soulières, Darrel Drachenberg, Frédéric Pouliot, Simon Tanguay

Publikováno v: Société Internationale d’Urologie Journal, Vol 2, Iss 2, Pp 82-95 (2021)

ObjectivesTo evaluate the role of incomplete metastasectomy (IM) for patients with metastatic renal cell carcinoma (mRCC) on overall survival (OS) and time to introduction of first-line systemic therapy. MethodsPatients diagnosed with mRCC between J

Externí odkaz: https://doaj.org/article/935b7e3a89ca49e38304305095c7d11e

Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis

Autor: Shen J, Chen Z, Fan M, Lu H, Zhuang Q, He X

Publikováno v: Cancer Management and Research, Vol Volume 11, Pp 5365-5374 (2019)

Jie Shen,* Zhen Chen,* Min Fan, Hao Lu, Qianfeng Zhuang, Xiaozhou HeDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, People’s Republic of China*These authors contributed equally to this work Background:

Externí odkaz: https://doaj.org/article/713af0cbad0a449091c79cd1ad54cb8a

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Autor: Lin Yang, Anna Alyasova, Dingwei Ye, Antonia Ridolfi, Luca Dezzani, Robert J. Motzer

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)

Abstract Background RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit of second-line everol

Externí odkaz: https://doaj.org/article/dcbf67ee409b4411a43e83222f00ae51

Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group

Autor: Bradley Alexander McGregor, Daniel Y.C. Heng, Shaan Dudani, Giovanni Zanotti, Georg A. Bjarnason, Ulka N. Vaishampayan, Frede Donskov, Lynn Huynh, J. Connor Wells, Marco A. J. Iafolla, John A. Steinharter, Aaron R. Hansen, Mei Sheng Duh, Marie-France Savard, Jeffrey Graham, Rose Chang

Publikováno v: Savard, M F, Wells, J C, Graham, J, Dudani, S, Steinharter, J A, McGregor, B A, Donskov, F, Bjarnason, G A, Vaishampayan, U N, Hansen, A R, Iafolla, M A J, Zanotti, G, Huynh, L, Chang, R, Duh, M S & Heng, D Y C 2020, ' Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group ', Oncologist, vol. 25, no. 5, pp. 422-430 . https://doi.org/10.1634/theoncologist.2019-0605
Oncologist

Background International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first-line treatment. Materials and Methods Adult patients with clear cell mRCC initiating f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97b3aa7cb9eb54b0f2a201b5cf81f1e4
https://doi.org/10.1634/theoncologist.2019-0605